Adalimumab and Ixekizumab Show Similar Joint Outcomes in PsA

by | Apr 6, 2026 | Health

Spread the love
Adalimumab and ixekizumab show comparable effectiveness in improving joint outcomes and achieving remission in patients with psoriatic arthritis over 12 months, according to a real-world study.
Medscape News UK

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments